Business Wire

Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress

Share

Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France.

These data show that INV-202, the company’s lead peripheral CB1 blocker, reduced renal injury in a murine model of Streptozotocin (STZ)-induced Diabetes. More specifically, INV-202 reduced glomerular injury, renal fibrosis and injury to proximal tubular epithelial cells, and also preserved podocyte structure and function. In particular, there was a marked, dose-dependent reduction in albuminuria in this model of diabetes and associated kidney injury.

“The study showed that treatment with INV-202 reduced the progression of nephropathy in STZ-induced diabetic mice. Improvements in kidney size, function, and renal matrix remodeling, with corresponding gene expression were noted with both doses of 0.3 mg/kg and 3 mg/kg of INV-202”, said Dr. Tony Jourdan, Research Lead at the National Institute of Health and Medical Research (Inserm) U1231 Lipids, Nutrition, Cancer Research Centre, in Dijon, France.

Dr. Glenn Crater, CMO at Inversago added: “These results may hold promise for those patients with diabetic kidney disease for whom such a potential therapy could further slow and delay the occurrence of end-stage renal disease.”

Based on these supportive preclinical results, along with encouraging Phase 1 results, Inversago is looking forward to launching Phase 2 clinical development for INV-202.

About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy. It is specifically designed to preferentially interact with peripheral CB1 receptors located in the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.

About STZ Model
In this treatment model of diabetic kidney disease, mice were allowed to develop complication of diabetes for twelve weeks after STZ injection. Then these C57BL6/J mice (8 per treatment group) were randomized to receive a daily oral dose of INV-202, 0.3 mg/kg and 3 mg/kg, or vehicle for four weeks. Five mice not treated with STZ were used as a non-diabetic control. At the end of treatment, urinary albumin to creatinine ratio (ACR), renal matrix remodeling, glomerular filtration and interstitial fibrosis were assessed in addition to glucose levels, body weight, and organ weights.

About Diabetic Nephropathy
Diabetic nephropathy (DN) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. No cure exists for this indication and available medications only help slowing the progression of the disease and control related complications. Inversago believes that the development of a peripheral CB1 blockade represents a promising therapeutic avenue for such a metabolic disorder.

About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF). For more information, visit inversago.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.
info@inversago.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GlobalLogic Achieves Green Sustainability Ranking via the NQC SupplierAssurance Platform6.7.2022 12:00:00 CEST | Press release

GlobalLogic Inc., a Hitachi Group company and a leader in Digital Engineering, today announced it has achieved a Green rating via the NQC SupplierAssurance platform—a cloud-based solution used by suppliers to determine their sustainability performance level. Based on the Self-Assessment Questionnaire (SAQ 4.0) and validated by the NQC Supplier Assurance Team for accuracy, the results show GlobalLogic earning a score of 72% in its market category of Engineering and Research Technology Based Services. That score is significantly higher than the category average of 47% across more than 1200 locations. The automotive industry in particular has increased its focus on green initiatives. Stringent regulations and standards requiring substantial improvements to automotive manufacturing practices and direct environmental impact have been implemented in various regions. Examples range from the European Commission’s EU 2019/631 regulation targeting vehicle CO2 emissions to numerous ISO standards

Zyxel Communications’ White-Box OLT Awarded VOLTHA Certification as part of ONF’s Continuous Certification Program6.7.2022 09:30:00 CEST | Press release

Zyxel Communications today announced its SDA 3016SS White-Box OLT has joined the Open Networking Foundation’s (ONF) Continuous Certification Program for VOLTHA™. The ongoing certification is part of Zyxel’s commitment to delivering service providers with the best technology that suits their needs. Zyxel’s White-Box OLT achieved its VOLTHA ONF certification by meeting a set of standards related to performance, agility and interoperability. In addition, the product must also pass ongoing daily tests as part of ONF’s Continuous Certification Program, which ensures any new features and product updates meet ongoing tests and compliance as part of the CI/CD development pipeline for VOLTHA. The OLT will be introduced alongside ONF’s release of VOLTHA version 2.10. VOLTHA is an open-source project, hosted by ONF, that creates an open broadband-access environment for service providers by promoting vendor-agnostic hardware and software development. The newest release, VOLTHA 2.10, focuses on inc

JAB’s Pinnacle Pet Group Expands Through Acquisition of Veterfina’s European Pet Insurance Business6.7.2022 09:00:00 CEST | Press release

JAB Holding Company (“JAB”) is pleased to announce the signing of a definitive agreement through which Pinnacle Pet Group (“PPG”) will acquire 100% of the shares in Veterfina Verzekeringsmaatschappij N.V. and its European subsidiaries (“Veterfina”), one of the largest and fastest growing pet insurance businesses headquartered in the Netherlands. The transaction is expected to close in Q4 2022, subject to customary closing conditions, including regulatory approvals. Financial terms of the agreement were not disclosed. As part of the agreement, founder and CEO Nico Schuurbiers will continue in his current role and maintain a minority stake in PPG alongside co-founder Han de Groot. PPG will provide significant growth equity to accelerate the European expansion and development of Veterfina’s multi-brand and omni-channel strategy. This will include the introduction of FIGO, JAB’s D2C pet insurance brand and digital platform, in select European markets. “We share JAB’s ambitions for the pet

SoSafe hires former Smartly.io exec and SaaS leader Felix Fichtl as CFO to continue the firm’s recent growth6.7.2022 09:00:00 CEST | Press release

SoSafe – a leading provider of cyber security awareness – has hired former Smartly.io exec and experienced SaaS operator Felix Fichtl as CFO. Fichtl brings with him more than a decade’s experience in building and scaling finance organisations across the SaaS industry. From both his previous role as CFO at the global social media advertising automation giant, Smartly.io to his time spearheading finance operations for market leaders zoovu (formerly SMARTASSISTANT) and SAP Hybris (now SAP CX). His appointment comes as SoSafe looks to build on its recent growth and bring its human-centric approach to cybersecurity to the assistance of even more companies on an international scale. SoSafe is currently the market leader in cybersecurity awareness in its home country of Germany, and is one of the leading providers across Europe. In January 2022, the company closed a $73 million Series B financing round, led by Highland Europe, to help fuel expansion into new territories and establish the firm

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance6.7.2022 07:50:00 CEST | Press release

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR). The resulting company, Aurobac Therapeutics SAS, will combine the best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure. The aspiration is to succeed in the fight against AMR, which is a major public health threat. Having routine surgery such as caesarean sections or hip replacements may become life threatening, and complications from common diseases such as diabetes and injuries or cuts will become harder to manage because of growing resistance to antibiotics in patients. “The rise of antibiotic-resi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom